MARKET

KZIA

KZIA

Kazia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.410
-0.260
-7.08%
Closed 16:00 07/10 EDT
OPEN
3.660
PREV CLOSE
3.670
HIGH
3.750
LOW
3.410
VOLUME
9.20K
TURNOVER
--
52 WEEK HIGH
9.74
52 WEEK LOW
2.266
MARKET CAP
24.61M
P/E (TTM)
-2.7405
1D
5D
1M
3M
1Y
5Y

EPS

KZIA News

More
Kazia Presents Further Paxalisib, Cantrixil Data At AACR, Reinforcing Positive Efficacy Signals For Both Drugs
SYDNEY, June 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing
Benzinga · 06/22 14:31
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
PR Newswire · 06/22 05:39
Kazia Therapeutics Shares Volatile Following Press Release Highlighting Paxalisib Phase 2 Data At ASCO
Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly
Benzinga · 06/01 14:39
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal
PR Newswire · 06/01 01:45
Iain Ross Is The Independent Chairman of the Board of Kazia Therapeutics Limited (ASX:KZA) And They Just Picked Up 19% More Shares
Simply Wall St. · 05/29 21:34
Did You Manage To Avoid Kazia Therapeutics' (ASX:KZA) Devastating 86% Share Price Drop?
Simply Wall St. · 05/25 05:49
Kazia Therapeutics up 18% premarket on positive paxalisib data
Seeking Alpha - Article · 04/08 12:46
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
PR Newswire · 04/07 13:00

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About KZIA

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
More

Webull offers kinds of Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ:KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.